But only people who haven't started Herceptin treatment will be able to get Perjeta for free.
The Breast Cancer Aotearoa Coalition has been lobbying for more than a year to get Perjeta publicly funded.
But the coalition was disappointed that HER2+ patients who had started Herceptin treatment won't qualify.
"[Perjeta] should be available to all New Zealand women with this form of the disease, not just those newly diagnosed," said chairwoman Libby Burgess.
The New Zealand Breast Cancer Foundation puts the number of Kiwis who won't qualify because they were already taking Herceptin at 160.
The decision to exclude these sufferers was "heartless", Evangelina Henderson, the foundation's chief executive, said.
"We call on Pharmac to make Perjeta available to people already battling this advanced disease here, to help those 160 New Zealanders have what could be a significantly longer time with their families."
The coalition was also campaigning for Pharmac to change its policy, allowing those already on Herceptin to get Perjeta, Burgess said.
Both Burgess and Henderson said Australian women who were already being treated with Herceptin were able to access Perjeta when it was first funded there 18 months ago.